Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: Genome landscape-based targets

Expert Review of Anticancer Therapy

Volumn 13, Issue 1, 2013, Pages 5-8

  Cho, William C S ^a   Roukos, Dimitrios H ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

breast cancer; drugs; genome; HER2 positive; trastuzumab; trastuzumab emtansine

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TDM 1; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER INCIDENCE; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; COPY NUMBER VARIATION; DRUG TARGETING; EXOME; GENE AMPLIFICATION; GENE SEQUENCE; GENOME ANALYSIS; HER2 GENE; HUMAN; METASTASIS; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TRANSCRIPTOMICS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAYTANSINE; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2;

EID: 84871537590     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.152     Document Type: Review

References (26)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987).
2. Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. 11(2), 81-92 (2011).
3. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
4. Marty M, Cognetti F, Maraninchi D et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 23(19), 4265-4274 (2005).
5. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006).
6. Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8), 1039-1043 (2010).
7. Krop IE, LoRusso P, Miller KD et al. A Phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 30(26), 3234-3241 (2012).
8. Verma S, Miles D, Gianni L et al.; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783-1791 (2012).
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
10. Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark. Med. 4(4), 583-586 (2010).
11. Roukos DH. Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev. Med. Devices. 7(8), 723-726 (2010).
12. Stephens PJ, Tarpey PS, Davies H et al.; Oslo Breast Cancer Consortium (OSBREAC). The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403), 400-404 (2012).
13. Shah SP, Roth A, Goya R et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403), 395-399 (2012).
14. Banerji S, Cibulskis K, Rangel-Escareno C et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486(7403), 405-409 (2012).
15. Ellis MJ, Ding L, Shen D et al. Wholegenome analysis informs breast cancer response to aromatase inhibition. Nature 486(7403), 353-360 (2012).
16. Curtis C, Shah SP, Chin SF et al.; METABRIC Group. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403), 346-352 (2012).
17. Ross-Innes CS, Stark R, Teschendorff AE et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481(7381), 389-393 (2012).
18. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat. Med. 17(3), 297-303 (2011).
19. Ideker T, Krogan NJ. Differential network biology. Mol. Syst. Biol. 8, 565 (2012).
20. Califano A, Butte AJ, Friend S, Ideker T, Schadt E. Leveraging models of cell regulation and GWAS data in integrative network-based association studies. Nat. Genet. 44(8), 841-847 (2012).
21. Camacho DF, Pienta KJ. Disrupting the networks of cancer. Clin. Cancer Res. 18(10), 2801-2808 (2012).
22. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12(1), 56-68 (2011).
23. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput. Biol. 8(2), e1002375 (2012).
24. Ecker JR, Bickmore WA, Barroso I, Pritchard JK, Gilad Y, Segal E. Genomics: ENCODE explained. Nature 489(7414), 52-55 (2012).
25. Pennisi E. Bioinformatics. New way to look at life. Science 338(6105), 317 (2012).
26. Gerstein MB, Kundaje A, Hariharan M et al. Architecture of the human regulatory network derived from ENCODE data. Nature 489(7414), 91-100 (2012).